Publications Zabadinostat CXD101 Phase I Study Results Eyre, 2018 CXD101 Phase 2a Cohort Expansion Booth, 2021 Immune modulation underpins the anti-cancer activity of HDAC inhibitors Blaszczak, 2021 CXD101 MSS CRC Phase 2 Study (CAROSELL) Results Saunders, 2022 The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity Liu, 2023 AT-101 (PRMT5) PRMT5 promotes cancer cell migration and invasion through the E2F pathway Barczak 2020 Arginine methylation regulates the p53 response Jansson, 2008 Arginine methylation controls growth regulation by E2F-1 Cho, 2012 Arginine Methylation-Dependent Reader-Writer Interplay Governs Growth Control by E2F-1 Zheng, 2013 Arginine methylation expands the regulatory mechanisms and extends the genomic landscape under E2F control Roworth, 2019 Combination of PRMT5 inhibitor with Vactosertib Hong, 2023 PCV (cancer vaccine) LncRNA-derived peptides are immunogenic and drive a potent antitumour response Barczak, 2023
